Comparative Pharmacology
Head-to-head clinical analysis: NIVESTYM versus ZARXIO.
Peer-Reviewed Evidence
Head-to-head clinical analysis: NIVESTYM versus ZARXIO.
NIVESTYM vs ZARXIO
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Filgrastim is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to G-CSF receptors on hematopoietic cells, stimulating proliferation, differentiation, and release of neutrophils from bone marrow.
ZARXIO (filgrastim-sndz) is a recombinant human granulocyte colony-stimulating factor (G-CSF) that binds to specific cell surface receptors on hematopoietic progenitor cells, stimulating proliferation, differentiation, and release of neutrophils from the bone marrow.
5 mcg/kg subcutaneously or intravenously once daily for up to 14 days until absolute neutrophil count reaches 10,000/mm³ after nadir; or 5 mcg/kg subcutaneously once daily for 5 days for mobilization of peripheral blood progenitor cells.
5 mcg/kg subcutaneously once daily. Round to nearest vial size (300 mcg/0.5 mL or 480 mcg/0.8 mL).
None Documented
None Documented
Terminal elimination half-life approximately 3.5 hours (subcutaneous) in healthy volunteers; in patients undergoing chemotherapy, half-life may be prolonged (up to 4-6 hours) due to neutrophil-mediated clearance.
Terminal elimination half-life is approximately 3.5-4.5 hours in healthy adults; prolonged in renal impairment (up to 40 hours in end-stage renal disease).
Primarily renal (via degradation to peptides and amino acids); <1% excreted unchanged. Biliary/fecal elimination is negligible.
Primarily renal (70-80% as unchanged drug) via glomerular filtration; biliary/fecal excretion is negligible (<5%).
Category C
Category C
Colony-Stimulating Factor
Colony-Stimulating Factor